Canola Oil

Dosage for Canola Oil varies significantly based on the intended clinical use. For Allergen Immunotherapy, the dosage is highly individualized. It typically begins with a 'build-up phase' where a very dilute extract (e.g., 0.05 mL of a 1:100,000 dilution) is injected subcutaneously once or twice weekly. The dose is gradually increased over 3 to 6 months until a 'maintenance dose' is reached, which is often 0.5 mL of a 1:10 or 1:20 dilution.

For Parenteral Nutrition, the dosage is calculated based on the patient's body weight and caloric needs. A typical adult dose of a lipid emulsion containing canola oil is 1.0 to 2.0 grams of fat per kilogram of body weight per day, not to exceed 60% of total daily calories. For Estrogenic Modulation via phytosterols, clinical studies have utilized doses ranging from 800 mg to 2,000 mg of plant sterols daily, often divided into two doses.

Canola Oil extracts are used in pediatric patients for allergy diagnosis and treatment. For Allergy Testing, there is no specific age limit, though skin reactivity may be lower in infants. For Immunotherapy, it is generally reserved for children 5 years of age and older who can communicate symptoms of a systemic reaction. The dosing schedule follows the same build-up and maintenance logic as adults but may be adjusted based on the child's sensitivity and weight.

In Neonatal Parenteral Nutrition, lipid emulsions containing canola oil are critical. Dosing typically starts at 0.5 to 1.0 g/kg/day and is increased cautiously to 3.0 g/kg/day under strict monitoring of serum triglyceride levels to prevent fat overload syndrome.

Renal Impairment

No specific dosage adjustments are required for Canola Oil allergenic extracts in patients with renal impairment. However, in parenteral nutrition, fluid status must be monitored closely to avoid volume overload.

Hepatic Impairment

Patients with severe hepatic impairment or biliary obstruction may require reduced doses of lipid emulsions containing canola oil, as the liver is the primary site for lipid metabolism and biliary excretion of phytosterols. Monitoring of liver function tests (LFTs) is mandatory.

Elderly Patients

Elderly patients should be started at the lower end of the dosing range for immunotherapy due to a higher prevalence of comorbid cardiovascular conditions that could complicate the management of an allergic reaction.

• Allergenic Extracts: These must be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis. The injection is given subcutaneously, usually in the posterior aspect of the upper arm. Patients must remain in the clinic for at least 30 minutes following the injection.
• Injectable Emulsions: Administered via a central or peripheral intravenous line. The infusion rate must be controlled using an infusion pump to prevent rapid lipid accumulation.
• Oral Forms: If taking phytosterol capsules, they should be taken with a meal to maximize absorption, as they require the presence of dietary fats and bile for optimal uptake.
• Storage: Most pharmaceutical canola oil extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze, as this can denature the allergenic proteins.

If a dose of Immunotherapy is missed, contact your allergist immediately. If the lapse is brief (a few days), the same dose may be given. If the lapse is several weeks, the dose may need to be reduced to ensure safety. For Parenteral Nutrition, a missed dose should be reported to the nutrition support team; do not 'double up' the infusion rate to catch up.

An overdose of allergenic extract can lead to severe systemic allergic reactions or anaphylaxis. Symptoms include generalized hives, swelling of the throat, wheezing, and a drop in blood pressure. In the case of Lipid Emulsion Overdose, 'Fat Overload Syndrome' may occur, characterized by hyperlipidemia, fever, hepatosplenomegaly, and coagulation disorders. Emergency treatment involves stopping the infusion and providing supportive care (epinephrine for anaphylaxis; lipid-lowering measures for fat overload).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

In the context of Allergen Immunotherapy, the most common side effects are localized to the injection site. These include:

• Local Swelling (Wheal): A raised, red area at the site of injection, often itching or feeling warm. This typically resolves within 24 hours.
• Erythema: Redness of the skin around the injection site.
• Pruritus: Intense itching at the injection site or occasionally on the palms and soles.

When used in Intravenous Lipid Emulsions, common side effects include:

• Nausea and Vomiting: Often related to the rate of infusion.
• Headache: A transient side effect during the initial stages of therapy.
• Increased Triglycerides: A common metabolic response to lipid administration.

• Fatigue: Some patients report feeling tired for several hours after an allergy injection.
• Dizziness: May occur if the patient is anxious or if a mild systemic reaction is beginning.
• Low-grade Fever: Occasionally seen with parenteral lipid administration.
• Myalgia: Muscle aches or general body discomfort.

• Lymphadenopathy: Swelling of the lymph nodes near the injection site.
• Vasovagal Reactions: Fainting or lightheadedness due to the injection process itself rather than the medication.
• Cholestasis: In long-term parenteral nutrition, canola oil components may contribute to bile stasis in the liver.

> Warning: Stop taking Canola Oil and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is the most serious risk of allergenic extracts. It is a life-threatening systemic allergic reaction. Symptoms include a sudden drop in blood pressure (shock), difficulty breathing, swelling of the tongue or throat, and a rapid, weak pulse.
• Angioedema: Deep tissue swelling, particularly around the face, lips, or eyes, which can obstruct the airway.
• Severe Bronchospasm: Sudden, severe wheezing or chest tightness that makes it difficult to breathe.
• Fat Overload Syndrome: A rare but serious complication of IV lipid therapy. Symptoms include sudden fever, yellowing of the skin or eyes (jaundice), unusual bleeding or bruising, and severe abdominal pain.
• Pancreatitis: Can occur if Canola Oil emulsions cause extremely high levels of serum triglycerides (usually >1,000 mg/dL).

Prolonged use of Canola Oil in Allergen Immunotherapy is generally well-tolerated, with the primary long-term effect being the desired desensitization. However, some patients may develop persistent subcutaneous nodules at injection sites. In the context of Parenteral Nutrition, long-term use of lipid emulsions can lead to PNALD (Parenteral Nutrition-Associated Liver Disease), though emulsions containing canola oil and fish oil are often used specifically to reduce this risk compared to pure soybean oil emulsions.

Regarding its Estrogenic Effects, long-term high-dose exposure to canola-derived phytosterols is still being studied. There is a theoretical risk that prolonged estrogen receptor agonism could influence hormone-sensitive tissues, though current evidence suggests these effects are generally mild and potentially cardioprotective.

There are currently no FDA Black Box Warnings specifically for Canola Oil as a single-ingredient allergenic extract. However, all allergenic extracts carry a general class warning regarding the risk of severe non-fatal and fatal systemic reactions (anaphylaxis). Clinicians are required to have emergency equipment, including epinephrine, available whenever these extracts are administered.

Report any unusual symptoms to your healthcare provider.

Canola Oil, when used as a clinical extract, must be handled with extreme caution. It is not interchangeable with culinary canola oil. Patients with a known history of severe anaphylaxis to rapeseed or related cruciferous vegetables (like broccoli or mustard) must be evaluated with extreme care before any exposure to the pharmaceutical extract.

No FDA black box warnings for Canola Oil. However, the FDA requires all Allergenic Extracts to be administered only by clinicians trained in the management of anaphylaxis. The labeling for these products emphasizes that 'systemic reactions may occur at any time,' even in patients who have previously tolerated the injections well.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Patients must be monitored for at least 30 minutes post-injection. Those with unstable asthma are at a significantly higher risk for fatal reactions and should not receive immunotherapy until their asthma is well-controlled.
• Hepatotoxicity: While Canola Oil itself is not directly hepatotoxic, its use in IV lipid emulsions requires monitoring of liver enzymes. Accumulation of lipids in the liver can lead to steatosis or cholestasis.
• Coagulation Disorders: High doses of lipids can interfere with platelet function. Patients with existing bleeding disorders or those on anticoagulants should be monitored closely when receiving Canola Oil-based emulsions.
• Infection Risk: IV lipid emulsions are excellent growth media for bacteria and fungi. Strict aseptic technique is required during administration to prevent catheter-related bloodstream infections.

Patients receiving Canola Oil therapy may require the following tests:

• Serum Triglycerides: To ensure the body is clearing the lipids effectively (target usually <200-400 mg/dL).
• Liver Function Tests (ALT, AST, Bilirubin): To monitor for parenteral nutrition-associated liver disease.
• Peak Flow/Spirometry: For asthma patients receiving immunotherapy, to ensure lung function is stable before each dose.
• Skin Test Reactivity: Periodic re-testing to assess the progress of desensitization.

Canola Oil generally does not affect the ability to drive. However, if a patient experiences a systemic reaction or receives epinephrine to treat a reaction, they should not drive until they have fully recovered and been cleared by a medical professional.

There is no direct interaction between Canola Oil and alcohol. However, alcohol consumption can cause vasodilation, which may theoretically increase the rate of absorption of an allergenic extract or mask the early symptoms of an allergic reaction. Patients are advised to avoid alcohol for several hours before and after receiving immunotherapy injections.

Discontinuing Canola Oil immunotherapy typically does not result in withdrawal symptoms. However, stopping the treatment prematurely will result in the loss of immunological tolerance, and the patient's allergy symptoms will likely return. If the treatment must be stopped due to a severe reaction, it should only be restarted at a much lower dose under expert supervision.

> Important: Discuss all your medical conditions with your healthcare provider before starting Canola Oil.

• Beta-Blockers (e.g., Propranolol, Atenolol): While not a direct chemical interaction with Canola Oil, patients taking beta-blockers are at high risk. If Canola Oil causes an allergic reaction, beta-blockers can make the reaction more severe and, more importantly, make the patient resistant to the effects of epinephrine (the primary treatment for anaphylaxis).

• ACE Inhibitors (e.g., Lisinopril): Similar to beta-blockers, ACE inhibitors may increase the risk of more severe systemic reactions to allergenic extracts or cause increased swelling (angioedema).
• Tricyclic Antidepressants (TCAs) and MAOIs: These medications can potentiate the effects of epinephrine if it is needed to treat a reaction to Canola Oil, leading to dangerous spikes in blood pressure.
• Anticoagulants (e.g., Warfarin): High concentrations of lipids, including those found in Canola Oil emulsions, can occasionally alter the Vitamin K-dependent clotting factors or platelet aggregation. Monitor INR closely when starting or stopping IV lipid therapy.

• Estrogen-containing Medications (HRT, Oral Contraceptives): Since Canola Oil is classified as an Estrogen Receptor Agonist, there may be additive effects when used with other estrogens. This could potentially increase the risk of estrogen-related side effects like blood clots or breast tenderness, although the clinical significance of this with standard doses is likely low.
• Statins: Phytosterols in Canola Oil compete with cholesterol for absorption. While often used together to lower LDL, this interaction should be monitored to ensure lipid targets are met without excessive reduction in fat-soluble vitamin absorption.

• High-Fat Meals: If taking oral phytosterol supplements derived from Canola Oil, a high-fat meal will significantly increase the absorption of the sterols. While this is often the goal, it should be done consistently.
• Vitamin K-Rich Foods: Large amounts of Canola Oil contain small amounts of Vitamin K1, which could theoretically interfere with Warfarin therapy if intake changes drastically.

• St. John's Wort: May induce enzymes that metabolize the phytosterol components of Canola Oil, potentially reducing their estrogenic or lipid-lowering efficacy.
• Saw Palmetto: Both Saw Palmetto and Canola Oil phytosterols may affect androgen/estrogen balance; the combination should be used with caution in patients with hormone-sensitive conditions.

• Serum Bilirubin: High levels of circulating lipids from Canola Oil emulsions can interfere with the colorimetric assays used to measure bilirubin, leading to falsely elevated or depressed readings.
• Blood Oxygen (Pulse Oximetry): In rare cases of severe hypertriglyceridemia (lipemia) caused by Canola Oil infusions, pulse oximetry readings may be inaccurate.

For each major interaction, the mechanism usually involves either pharmacodynamic synergy (e.g., the combined effect on blood pressure or the immune system) or competitive absorption in the gut. Management typically involves careful timing of doses, increased frequency of lab monitoring, or choosing alternative medications that do not carry the same risks.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Canola Oil clinical products must NEVER be used in the following circumstances:

• Severe Uncontrolled Asthma: Patients with a forced expiratory volume in 1 second (FEV1) of less than 70% of predicted are at an unacceptably high risk for fatal bronchospasm during immunotherapy.
• Acute Myocardial Infarction or Unstable Angina: The physiological stress of a potential systemic allergic reaction could be fatal in these patients.
• Known Hypersensitivity to Any Component: This includes not just the Canola proteins but also any preservatives (like phenol) or emulsifiers (like egg phospholipids) used in the pharmaceutical preparation.
• Severe Hyperlipidemia: For IV emulsions, patients with baseline triglycerides above 1,000 mg/dL should not receive Canola Oil-based lipids due to the risk of acute pancreatitis.

Conditions requiring a careful risk-benefit analysis include:

• Autoimmune Diseases: Immunotherapy could theoretically exacerbate conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis, although data are inconclusive.
• Beta-Blocker Therapy: As mentioned, this makes treating a reaction difficult. If the beta-blocker cannot be stopped, the doctor must weigh the need for the Canola Oil extract against the increased safety risk.
• Malignancy: Because Canola Oil is an Estrogen Receptor Agonist, its use in patients with active, hormone-sensitive cancers (such as certain types of breast or endometrial cancer) should be approached with extreme caution.

Patients allergic to Canola Oil may also react to other members of the Brassicaceae family. This includes:

• Mustard Seed
• Rapeseed/Colza
• Broccoli, Cabbage, and Brussels Sprouts

Cross-reactivity is due to the presence of highly conserved proteins like the 2S albumin (napin). If a patient has a known severe allergy to mustard, they should be treated as if they are also allergic to Canola Oil extracts until proven otherwise.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Canola Oil.

FDA Pregnancy Category: Not formally assigned for the allergenic extract, but generally considered Category C.

There are no adequate and well-controlled studies of Canola Oil allergenic extracts in pregnant women. For Immunotherapy, it is generally recommended not to start a new build-up phase during pregnancy due to the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen). However, if a woman is already on a stable maintenance dose and is tolerating it well, the treatment may be continued.

Regarding its Estrogen Receptor Agonist properties, high doses of phytosterols during pregnancy are generally avoided as they could theoretically interfere with the delicate hormonal balance required for fetal development. However, the amounts found in standard dietary or IV lipid sources are considered safe.

It is unknown whether the specific allergenic proteins or concentrated phytosterols from Canola Oil extracts pass into human breast milk. Most experts believe that the lipid components are safe and actually beneficial, as they contribute to the essential fatty acid profile of the milk. Caution should be exercised when administering immunotherapy to a nursing mother, primarily due to the risk of a systemic reaction in the mother rather than direct harm to the infant.

Canola Oil is approved for use in children for both allergy diagnosis and as a component of parenteral nutrition. In the NICU, it is a vital source of calories. However, the 'Estrogen [EPC]' effects in children are not well-characterized. Long-term studies on the impact of phytosterols on pediatric endocrine development are limited, though no adverse signals have been identified in children receiving standard lipid emulsions.

Elderly patients (over 65) may have a diminished immune response to Canola Oil immunotherapy. They are also more likely to have underlying cardiovascular disease, which increases the risk associated with a systemic reaction. In parenteral nutrition, the elderly are at higher risk for hypertriglyceridemia and should have their lipid levels monitored more frequently.

In patients with kidney failure, the clearance of the metabolites of Canola Oil is not significantly affected. However, these patients are often at higher risk for cardiovascular complications, and the lipid-modulating effects of Canola Oil (via its phytosterols and unsaturated fats) may be beneficial. Monitoring for fluid and electrolyte balance is the primary concern during IV administration.

As the liver is the primary organ for lipid processing, patients with Child-Pugh Class B or C impairment must be monitored closely. Canola Oil-based emulsions are often preferred over soybean-only emulsions in these patients because they contain less omega-6 fatty acids, which are thought to be more pro-inflammatory and damaging to the liver.

> Important: Special populations require individualized medical assessment.

Canola Oil's pharmacology is multifaceted. As an Allergenic Extract, it functions as an immunomodulator. The 2S albumin (Napin) and 12S globulin (Cruciferin) proteins in the oil act as antigens that bind to IgE on mast cells (diagnostic) or induce T-cell tolerance (therapeutic).

As an Estrogen Receptor Agonist, the mechanism is molecularly distinct. The phytosterols (beta-sitosterol, campesterol) enter the cell and bind to the ligand-binding domain of Estrogen Receptors Alpha and Beta. This binding induces a conformational change that allows the receptor to dimerize and translocate to the nucleus, where it binds to Estrogen Response Elements (EREs) on DNA, modulating the transcription of genes involved in lipid metabolism and cell growth.

• Immunological Onset: Skin prick reactions occur within 15-20 minutes. Immunotherapy effects take 6-12 months to become clinically significant.
• Hormonal Onset: Phytosterol-mediated effects on cholesterol and estrogenic signaling typically require 2-4 weeks of consistent exposure.
• Duration: The desensitizing effect of immunotherapy can last for years after the treatment course is completed (typically 3-5 years of therapy).

| Parameter | Value |

|---|---|

| Bioavailability | >95% (Lipids/Oral); Variable (Proteins/SubQ) |

| Protein Binding | >99% (Lipid components bound to albumin/lipoproteins) |

| Half-life | 24-48 hours (Chylomicron clearance) |

| Tmax | 4-6 hours (Oral ingestion) |

| Metabolism | Hepatic (Beta-oxidation and CYP-mediated sterol metabolism) |

| Excretion | Biliary/Fecal (>90%); Renal (<5%) |

• Molecular Formula: Complex mixture (Primary components: C18H34O2 - Oleic Acid; C29H50O - Beta-sitosterol)
• Molecular Weight: Varies by component (Phytosterols ~414.7 g/mol)
• Solubility: Highly lipophilic; insoluble in water; soluble in organic solvents and oils.
• Structure: A triglyceride-rich oil with a high proportion of monounsaturated and polyunsaturated fatty acids, containing a sterol fraction with a tetracyclic cyclopenta[a]phenanthrene skeleton.

Canola Oil belongs to the Non-Standardized Food Allergenic Extract [EPC] class. It is also categorized under Estrogen [EPC] due to its phytosterol content. It is closely related to other vegetable oil extracts like Soybean Oil and Peanut Oil extracts used in similar clinical capacities.